Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of ponesimod in relapsing-remitting multiple sclerosis
NL-OMON55638Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2011
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ponesimod in relapsing-remitting multiple sclerosis (RRMS) (9 arms), sponsored by Janssen Pharmaceutical. Started Feb 2011; status: active, not recruiting.
02
Drugs
ponesimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NL-OMON55638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55638.